NRX Pharmaceuticals (NRXP) Capital Expenditures (2021 - 2023)
NRX Pharmaceuticals (NRXP) posted quarterly Capital Expenditures of -$1000.0 for Q4 2023, little changed year-over-year from -$1000.0 in Q4 2022, and down 150.0% quarter-over-quarter from $2000.0 in Q3 2023.
NRX Pharmaceuticals (NRXP) Capital Expenditures (2021 - 2023) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Capital Expenditures for 3 consecutive years, with -$1000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Capital Expenditures changed 0.0% year-over-year to -$1000.0; the TTM figure through Sep 2024 stood at -$1000.0 (down 133.33% YoY), while the FY2023 annual figure was $3000.0, down 70.0% from the prior year.
- Capital Expenditures slipped to -$1000.0 in Q4 2023 per NRXP's latest filing, from $2000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $5000.0 in Q3 2022 and bottomed at -$2000.0 in Q2 2023.
- Historically, Capital Expenditures has averaged $1888.9 across 3 years, with a median of $3000.0 in 2022.
- On a YoY basis, Capital Expenditures climbed as much as 33.33% in 2023 and fell as far as 166.67% in 2023.
- NRX Pharmaceuticals' Capital Expenditures stood at $4000.0 in 2021, then tumbled by 125.0% to -$1000.0 in 2022, then changed by 0.0% to -$1000.0 in 2023.
- Business Quant data shows NRXP's Capital Expenditures at -$1000.0 in Q4 2023, $2000.0 in Q3 2023, and -$2000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -1,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Sep 30, 2023 | 2,000.00 |
| Sep 30, 2023 | 2,000.00 |
| Jun 30, 2023 | -2,000.00 |
| Jun 30, 2023 | -2,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Dec 31, 2022 | -1,000.00 |
| Dec 31, 2022 | -1,000.00 |
| Sep 30, 2022 | 5,000.00 |
| Sep 30, 2022 | 5,000.00 |
| Jun 30, 2022 | 3,000.00 |
| Jun 30, 2022 | 3,000.00 |
| Mar 31, 2022 | 3,000.00 |
| Mar 31, 2022 | 3,000.00 |
| Sep 30, 2021 | 4,000.00 |
| Sep 30, 2021 | 4,000.00 |